Taurina

Taurine (2-Aminoethanesulfonic Acid): A Comprehensive Reference

1. Identity, Chemical Characterization, and Natural Sources

Chemical Identity

Taurine (IUPAC name: 2-aminoethanesulfonic acid) is a naturally occurring organic compound with the chemical formula H₂N−CH₂−CH₂−SO₂−OH in its non-zwitterionic form, and is a non-proteinogenic amino sulfonic acid widely distributed in mammalian tissues and organs. By containing a sulfonic acid group instead of a carboxylic acid group, it is not involved in protein synthesis but is still usually referred to as an amino acid; as a non-proteinogenic amino sulfonic acid, it is not encoded by the genetic code and is distinguished from the protein-building α-amino acids.

Taurine is referred to as a conditional amino acid because it is derived from cysteine like other amino acids, but lacks a carboxyl group that usually belongs to amino acids. Instead, it contains a sulfide group and can be called an amino sulfonic acid. Taurine is a multifunctional sulfur-containing amino acid and conditionally essential nutrient for humans, playing a key role in various biological processes.

Discovery and Naming

Taurine was first isolated in 1827 by two German scientists, Friedrich Tiedemann and Leopold Gmelin, who discovered the presence of the substance in the bile of an ox. The name "taurine" is derived from the Latin term taurus, meaning bull or ox.

Distribution in the Body

Taurine is one of the most abundant free amino acids in the human body, and a 70 kg person can contain up to 70 g of taurine. In mammals, taurine is almost ubiquitous in distribution, with high concentrations in electrically excitable tissues (heart and brain), retina, platelets, and secretory structures. Taurine is a major constituent of bile and can be found in the large intestine.

Natural Dietary Sources

Taurine exists naturally in animals including mammals, birds, fish, and aquatic invertebrates such as oysters and mussels. Although plants contain less than 1% of the taurine levels found in animals, the most taurine-rich plants are algae, followed by fungi and other terrestrial plants. Typical daily taurine intake from food ranges from 40–400 mg/day.

Endogenous Biosynthesis

Among the diverse pathways by which natural taurine can be biosynthesized, its pathways in the human liver are from cysteine and/or methionine. Mammalian taurine synthesis occurs in the liver via the cysteine sulfinic acid pathway. Taurine is naturally synthesized in the pancreas of the human body via a process called the cysteine sulfinic acid pathway. This involves the oxidation of the sulfhydryl group on the cysteine molecule to form cysteine sulfinic acid, which undergoes decarboxylation to form hypotaurine and eventually taurine. Key enzymes cysteine dioxygenase (CDO) and cysteine sulfinate decarboxylase (CSAD) are critical for the natural biosynthesis of taurine.

Commercial Production and Common Forms

The majority of taurine is produced by chemical synthesis because extraction is less efficient, more costly, and initial materials (e.g., bovine or ovine bile) are not available in sufficient amounts to meet global market demand. As public consumer demand for taurine has increased, commercial production of the substance has become necessary, with the introduction of chemical synthesis. This is usually done with a reaction between ethylene oxide and sodium bisulfite to form isethionic acid, which is used to obtain the synthetic form of taurine. Taurine is currently produced in an amount of over 60,000 tons per year from either ethylene oxide or monoethanolamine.

Taurine is commercially available in several forms, including:

• Oral powder (bulk and sachets)
• Capsules and tablets
• Added ingredient in energy drinks
• Component of infant formula (for preterm infants)
• Intravenous/parenteral preparations (clinical/pharmaceutical use)

Despite popular myths, the taurine used in energy drinks is synthetically produced and is not derived from animal sources.

2. Traditional and Historical Use

Traditional Chinese and Japanese Medicine

Calculus Bovis (Goo in Japanese, Niuhuang in Chinese — the gallstone of Bos Taurus domesticus Gmelin) is one of the most precious and commonly-used medicinal materials in Japan and China. Its use was first recorded in the Shennong Bencao Jing (Divine Farmer's Materia Medica Classic) more than two thousand years ago, and it has been used in 650 out of 4,500 traditional Chinese medicines. In the 230 cardioactive types of Japanese OTC drugs, 228 drugs contain C. Bovis, which has the effects of sedation, anti-hyperspasmic activity, relieving fever, diminishing inflammation, and normalizing function of the gallbladder.

Artificial C. Bovis is a mixture of bile salts, bilirubin, taurine, and some other ingredients that have been found and believed to have contributed to the therapeutic effects of natural C. Bovis. Taurine partly attenuated the harmful actions of bile acids, and it is plausible that the relationship between taurine and the bile acids contributes to the therapeutic effect of C. Bovis.

19th and Early 20th Century — Scientific Isolation and Initial Study

For much of the 19th and early 20th centuries, taurine was largely ignored outside of veterinary circles. It was studied mainly for its role in bile acid conjugation, helping to emulsify dietary fats. Early animal studies revealed taurine's importance for the health of domestic animals, but its broader significance for human health would only come to light much later.

Scientists pursued its potential medicinal uses, which were discovered in part because cats cannot produce taurine and are subject to severe ailments when it is absent from their diet.

Modern Clinical Recognition in Japan

In 1985, taurine was first approved as a treatment for heart failure patients in Japan. More recently, taurine has been approved in Japan for treating stroke-like episodes in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), a mitochondrial disease.

Entry into the Global Supplement Market

Taurine started to gain recognition and usage during the 1990s, primarily driven by the rise of energy drinks and the expanding dietary supplement market. In Europe, the use of taurine in food and supplements came into focus during the early 2000s. Taurine initially gained attention through its incorporation in energy drinks and subsequently expanded to other product categories.

3. Key Constituents, Biochemistry, and Mechanisms of Action

Structural Basis of Activity

Taurine is a non-proteinogenic amino sulfonic acid, meaning it contains a sulfonic acid group (−SO₃H) instead of the typical carboxylic acid group (−COOH) found in protein-building amino acids. This unusual structure underlies its broad biological activity across multiple physiological systems.

Established Mechanisms

The cytoprotective actions of taurine contribute to the improvement of clinical and nutritional health of humans through various mechanisms, including antioxidation, energy production, neuromodulation, Ca²⁺ homeostasis, and osmoregulation. A detailed account of each mechanism follows:

• Osmoregulation and Cell Volume Regulation: Taurine is an organic osmolyte involved in cell volume regulation and provides a substrate for the formation of bile salts. Its ability to accumulate intracellularly and be released in response to osmotic stress helps cells maintain volume homeostasis.
• Antioxidant Activity: There have been numerous reports indicating taurine as an effective antioxidant, but the mechanism underlying its antioxidant activity remains not fully understood. The best-established antioxidant action of taurine is neutralization of hypochlorous acid (HOCl), an extremely toxic oxidant generated by the myeloperoxidase–halide system. The amino group of taurine can neutralize hypochlorous acid, one of the reactive species generated by neutrophils. In that reaction, taurine is converted to taurine chloramine, which is less toxic than hypochlorous acid and serves as a modulator of the immune system. The sulfonic acid moiety of taurine is incapable of scavenging common oxidants such as superoxide, hydrogen peroxide, and hydroxyl radical.
• Calcium Homeostasis: Taurine plays a role in the modulation of intracellular free calcium concentration. Dysregulation of intracellular Ca²⁺ is associated with ischemic injury and heart failure, and taurine's buffering of this signal is a key mechanism in its cardioprotective effects.
• Bile Acid Conjugation: Taurine is an ideal modulator of various basic processes, including bile acid conjugation and lipid metabolism. Taurine conjugates to cholesterol, promoting cholesterol excretion through bile salt formation and fat digestion.
• Neuromodulation: Taurine satisfies many of the criteria considered essential for inclusion in the inventory of neurotransmitters, but evidence of a taurine-specific receptor has yet to be identified in the vertebrate nervous system. Its neuroprotective effect is observed against L-glutamate-induced excitotoxicity, whereby it counteracts the glutamate-induced increase of intracellular calcium through voltage-gated calcium channels and the NMDA receptor, thus preventing glutamate-induced membrane depolarization.
• Membrane Stabilization: Taurine stabilizes membranes through direct interactions with phospholipids. Its inhibition of the enzyme phospholipid N-methyltransferase alters the phosphatidylcholine and phosphatidylethanolamine content of membranes, which in turn affects the function of key proteins within the membrane.
• Mitochondrial Function: Accumulating studies have shown that taurine supplementation protects against pathologies associated with mitochondrial defects, such as aging, mitochondrial diseases, metabolic syndrome, cancer, cardiovascular diseases, and neurological disorders. One important mitochondrial mechanism involves the modification of mitochondrial tRNA, where taurine participates in the synthesis of 5-taurinomethyluridine, a modification critical for the efficient translation of mitochondrial proteins.
• Anti-Inflammatory Effects: Taurine reduces the levels of different cytokines (including interleukin (IL)-1α, IL-1β, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17, and tumor necrosis factor (TNF-α)) during disease or injury, as shown in preclinical and clinical studies.

4. Scientific Evidence by Area of Use

4.1 Cardiovascular Health

Heart Failure

Taurine accounts for approximately 50% of the total free amino acids in the heart; it has been shown to enhance cardiac contractility and improve heart function in both human and animal models.

In a double-blind crossover trial involving 14 patients with congestive heart failure (CHF) published in 1985, taurine supplementation showed improvements in the treatment group. In this study, researchers supplemented 6 g/day of taurine for 4 weeks, with a 2-week washout period before crossing over the groups. Clinico-radiographic parameters were used to assess severity of heart failure. Twelve of 14 patients in the treatment group demonstrated improvements compared to 3 of 14 in the placebo group.

Patients (n = 17) with congestive heart failure (ejection fraction ≤ 50%) given 3 g/day taurine for 6 weeks showed significant improvement in systolic left ventricular function compared to the control CoEnzyme Q10-treated group.

There is a wealth of experimental information and some clinical evidence available in the literature suggesting that taurine could be of benefit in cardiovascular disease of different etiologies. However, double-blind long-term clinical trials need to be conducted before taurine can be unequivocally recommended as a nutritional intervention for the prevention and/or treatment of cardiovascular disease.

Blood Pressure

A higher dose of taurine (6 g/day for 7 days) decreased blood pressure in patients with hypertension. The mechanisms in these studies were shown to be dependent on the modulation of an overactive sympathetic system.

Taurine holds promise for cardiovascular health through mechanisms such as calcium regulation, blood pressure reduction, and antioxidant and anti-inflammatory effects. Despite these potential benefits, previous studies have yielded inconsistent results. A meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the existing evidence on the quantitative effects of taurine on hemodynamic parameters and cardiac function grading.

The impact of taurine on systolic blood pressure is diminished in patients with hypertension and diabetes, who generally have elevated baseline SBP. Conversely, taurine effectively lowers diastolic blood pressure (DBP) in patients with hypertension and heart failure.

Type 2 Diabetes and Vascular Function

A randomized, double-blind, placebo-controlled trial enrolled diabetic patients (aged 60.0 ± 8.6 years in the taurine group, N = 82; and 59.1 ± 10.4 years in the placebo group, N = 83), who received either taurine (2.4 g/day) or placebo for 12 weeks. Taurine significantly inhibited the activation of platelet calcium influx in patients with type 2 diabetes (T2D) and may exert beneficial effects on blood pressure and vascular dysfunction in patients with T2D.

Clinical studies also demonstrated that patients with type-2 diabetes following supplementation of taurine (500 mg three times per day for 2 weeks) attenuated vascular dysfunction assessed by lower flow-mediated dilation (FMD), indicating that taurine alone reverses endothelial dysfunction, which is the primary path to atherosclerosis.

Evidence assessment: The cardiovascular evidence base consists of multiple small-to-medium RCTs and several meta-analyses. Taurine holds promise for cardiovascular health through mechanisms such as calcium regulation, blood pressure reduction, and antioxidant and anti-inflammatory effects; however, previous studies have yielded inconsistent results. Larger, long-term, adequately powered trials remain needed.

4.2 Metabolic Syndrome

Metabolic syndrome (MetS) is a cluster of interconnected risk factors that significantly increase the likelihood of cardiovascular disease and type 2 diabetes. Taurine has emerged as a potential therapeutic agent for MetS.

Taurine plays a pivotal role in regulating glucose and lipid metabolism, blood pressure homeostasis, and obesity, largely due to its cytoprotective, antioxidant, and anti-inflammatory actions. Despite promising data from animal studies, the efficacy of taurine supplementation in human studies has been inconsistent.

A meta-analysis of randomized controlled trials aimed to evaluate the effects of taurine supplementation on MetS-related parameters, based on electronic searches through Embase, PubMed, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov. The analysis focused on systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG), triglyceride (TG), and high-density lipoprotein cholesterol (HDL-C).

Evidence assessment: The evidence for taurine's benefit in metabolic syndrome comes primarily from RCTs of short-to-moderate duration. While favorable signals have been observed in several parameters, heterogeneity across trials limits definitive conclusions.

4.3 Exercise Performance and Recovery

Taurine has become a popular supplement among athletes attempting to improve performance. While the effectiveness of taurine as an ergogenic aid remains controversial, the evidence addresses its efficacy in aerobic and anaerobic performance, metabolic stress, muscle soreness, and recovery.

Peer-reviewed studies investigated taurine as a single ingredient at dosages of less than 1 g to 6 g, ranging from 10–15 minutes to 2 hours prior to an exercise bout, or as a chronic dose (7 days to 8 weeks) of consumption.

Rutherford and colleagues showed that taurine supplementation (1.66 g ingestion) increased fat oxidation by up to 16% in athletes during exercise, compared to placebo, and this may be due to the activation of adenylate cyclase.

In a double-blind, placebo-controlled crossover study, 30 young male speed skaters were randomly assigned to either taurine (single dose of 6 g) or placebo 60 minutes before testing. Following a 72-hour washout, participants completed the opposite condition. Taurine improved peak (Δ% = 13.41), mean (Δ% = 3.95), and minimum power output (Δ% = 7.89) compared to placebo.

Despite the theoretical benefits of taurine supplementation, its clinical effects on markers of muscle damage and muscle pain have been inconsistent. Some RCTs have reported a significant reduction in creatine kinase (CK) and lactate dehydrogenase (LDH) levels, suggesting protective effects on muscle integrity following exercise. Other studies have found no meaningful impact on these markers or on subjective measures of muscle soreness. Such discrepancies may arise from variations in study design, taurine dosage, duration of supplementation, timing of administration, and population characteristics.

Collectively, findings from a recent meta-analytic review suggest that acute single-dose taurine supplementation holds promise as an ergogenic aid, but its effectiveness likely varies depending on dosage, blinding procedures, and exercise context. Additional high-quality trials are needed to establish more definitive recommendations.

Evidence assessment: Preliminary to moderate. Evidence shows some benefits in fat oxidation and short-burst anaerobic power, but results are inconsistent across modalities and populations. Most trials involve small sample sizes and short durations.

4.4 Neurological Health and Neuroprotection

Taurine is able to cross the blood-brain barrier and displays multiple functions in the central nervous system (CNS), including neuromodulation, osmoregulation, the maintenance of calcium homeostasis, membrane stabilization, anti-oxidation, anti-inflammation, and neuroprotection, and is also seen as a trophic factor during CNS development.

Obesity, type 2 diabetes, and their associated comorbidities impact brain metabolism and function. Alterations to taurine homeostasis can impact biological processes such as osmolarity control, calcium homeostasis, and inhibitory neurotransmission, and have been reported in both metabolic and neurodegenerative disorders.

The neuroprotective effects of taurine have received considerable attention, and there is a plethora of publications showing the ability of exogenously added taurine to prevent toxicity in neurons or astrocytes in vitro, as well as in animal models of neurological disorders. Taurine treatments have been shown to protect tissues and cells against oxidative stress, mitochondrial stress, and inflammation.

MELAS (Mitochondrial Disease)

Taurine has been approved in Japan for treating stroke-like episodes in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). A multicentre, open-label, 52-week phase III trial investigated taurine supplementation for prevention of stroke-like episodes in MELAS (published in the Journal of Neurology, Neurosurgery & Psychiatry, 2019). This represents one of taurine's most evidentially supported therapeutic applications.

Evidence assessment: The strongest neurological evidence is in MELAS, where taurine has regulatory approval in Japan. For other neurological conditions, the evidence base in humans remains primarily preclinical (animal and in vitro), and robust clinical trial data are limited.

4.5 Ocular Health and Retinal Protection

Taurine may be especially important for the retina. The concentration of taurine in the retina is higher than that in any other tissue in the body, and taurine deficiency causes retinal oxidative stress, apoptosis, and degeneration of photoreceptors and retinal ganglion cells. Low plasma taurine levels may also underlie retinal degeneration in humans, and therefore taurine administration could exert retinal neuroprotective effects.

The retinal toxicity of the antiepileptic drug vigabatrin is caused by taurine depletion. Vigabatrin-treated rats and mice exhibit lower plasma taurine concentration, and taurine supplementation decreased the observed photoreceptor degeneration and the consecutive disorganization of the photoreceptor layers.

A clinical study associating taurine, a calcium channel blocker (diltiazem), and vitamin E was reported to improve vision in patients with retinitis pigmentosa.

Evidence assessment: The strongest retinal evidence concerns drug-induced (vigabatrin) taurine depletion, which is documented in both animal models and clinical observation. Evidence for taurine supplementation in idiopathic retinal degeneration in humans remains early-stage.

4.6 Mitochondrial Health and Aging

Concentrations of circulating taurine decline with aging in mice, monkeys, and humans. A reversal of this decline through taurine supplementation increased the health span (the period of healthy living) and life span in mice and health span in monkeys. Mechanistically, taurine reduced cellular senescence, protected against telomerase deficiency, suppressed mitochondrial dysfunction, decreased DNA damage, and attenuated inflammaging.

In humans, lower taurine concentrations correlated with several age-related diseases, and taurine concentrations increased after acute endurance exercise. To test whether taurine deficiency is a driver of aging in humans, long-term, well-controlled taurine supplementation trials that measure health span and life span as outcomes are required.

However, findings from the landmark 2023 Science paper by Singh et al. have been actively scrutinized. A subsequent study found that circulating taurine concentration is not associated with age, muscle mass, strength, physical performance, or mitochondrial function in humans. Taurine deficiency is therefore unlikely to be a primary driver of aging in humans. Taurine recently gained popularity as a dietary supplement due to research that found supplementation with taurine improved multiple age-related traits and extended lifespan in model organisms (worms and mice). However, there is no solid clinical data that shows its supplementation benefits humans in terms of aging outcomes.

Evidence assessment: Preliminary and under active debate. Robust evidence exists for taurine's role in aging in non-human model organisms. Translation to human longevity outcomes is currently unsupported by clinical trial data, and contradictory findings in human cohort data have been published (as of 2025, per NIH/NIA research).

4.7 Liver Health

Taurine combines with bile acids to exert antioxidant and anti-fibrosis effects and can attenuate alcohol-induced liver injury by inhibiting hepatic stellate cell (HSC) activation. Taurine treatments have been shown to ameliorate the onset and development of fatty liver by exerting antioxidant, anti-inflammatory, and antiapoptotic effects.

Evidence assessment: Liver-related evidence is primarily preclinical. Some clinical data exist from parenteral nutrition studies where taurine-supplemented regimens improved liver function markers. Human RCT data specifically targeting liver disease as a primary endpoint are limited.

5. Body Systems Associated with Taurine

Based on the converging scientific literature, taurine has been associated with the following body systems and health areas:

• Cardiovascular system: Protection against ischemia-reperfusion injury, modulation of intracellular calcium concentration, and antioxidant, antiatherogenic, and blood pressure-lowering effects.
• Central nervous system: Modulation of neuronal excitability, cerebral control of the cardiorespiratory system, appetite regulation, resistance to hypoxia, osmoregulation, and anti-oxidation.
• Visual system/retina: Antioxidant, anti-apoptotic, immunomodulatory, and calcium homeostasis-regulatory properties relevant to retinal health.
• Skeletal muscle: Vital to preserving cellular integrity in cardiac, ocular, hepatic, renal, skeletal muscle, and central nervous system tissues.
• Liver and digestive system: Bile acid conjugation, cholesterol metabolism, and hepatoprotection.
• Mitochondria: Taurine is found abundantly in excitatory tissues such as the heart, brain, retina, and skeletal muscles, where mitochondrial activity is particularly high.
• Immune system: Via taurine chloramine formation from reaction with HOCl, modulating neutrophil and macrophage activity.

6. Dosage Forms and Dosages Reported in Studies

Taurine has been tested across a wide range of doses in human clinical research. The following dosages have been directly reported in peer-reviewed sources:

• Typical daily dietary intake from food ranges from 40–400 mg/day.
• Taurine doses in published human trials have ranged from 500 mg/day to 10 g/day.
• Dosages are categorized in the sports science literature as low (0.5–2 g), moderate (3–5 g), and high (greater than 5 g).
• In the landmark 1985 double-blind crossover CHF trial, 6 g/day of taurine was used for 4 weeks.
• In a CHF study, 3 g/day was used for 6 weeks.
• A dose of 6 g/day for 7 days decreased blood pressure in patients with hypertension.
• 500 mg three times per day (1.5 g/day) for 2 weeks was studied for vascular function in type 2 diabetes.
• 2.4 g/day for 12 weeks was used in a recent RCT of diabetic patients with peripheral arterial disease.
• A single dose of 6 g was administered 60 minutes before exercise in a speed-skating anaerobic performance trial.
• The highest oral dosage used in randomized controlled trials reviewed by Shao and Hathcock was 150 mg/kg/day or approximately 10 g/day over 6 months.
• A risk assessment study by Shao and colleagues established the upper level of taurine supplementation at 3 g per day. The only adverse effects noted after consuming a 3 g dose were gastrointestinal disorders. The minimum dose used in these trials was 3 g/day, much greater than the usual intake of taurine from a normal diet (less than 0.4 g/day).

7. Safety Profile, Toxicology, and Drug Interactions

General Safety Profile

Based on published reports and the opinions of EFSA and SCF, taurine does not have any potential for reproductive or developmental toxicity, mutagenicity, genotoxicity, or carcinogenicity.

The safety of supplementation was comprehensively reviewed by Shao and Hathcock with the Council for Responsible Nutrition, who examined 30 peer-reviewed, published controlled clinical trials in humans involving administration of taurine. No significant adverse effects were seen in any trial.

Regulatory Safety Determinations

EFSA confirmed a No Observed Adverse Effect Level (NOAEL) of 1,000 mg per kilogram of bodyweight per day. Taurine and d-glucuronolactone occur as natural ingredients in food and are normal human metabolites. However, they are also used at much higher levels in energy drinks.

Based on human studies, an intake of approximately 21 mg/kg body weight per day is considered unlikely to cause adverse health effects. An 18-month study showed that dietary administration of taurine up to 2,500 mg/kg bw/day produced no treatment-related adverse effects in male or female rats.

Observed Adverse Effects

Variable findings reported in reviewed studies include gastric discomfort, increased as well as decreased triglycerides, and decreased blood pressure in hypertensive individuals (but not in other patients). The only adverse effects noted in a key safety assessment after consuming a 3 g dose of taurine were gastrointestinal disorders.

Energy Drinks and Combined Ingredient Concerns

Cardiovascular events have been reported following excessive consumption of energy drinks; however, it is difficult to attribute these events directly to taurine because the drinks contain multiple ingredients and their consumption is often accompanied by excessive alcohol intake or physical activity.

Based on new data from human studies, EFSA considered that cumulative interactions between taurine and caffeine with regard to diuretic effects (the loss of water and sodium from the body) were unlikely.

Special Populations: Vegans and Low-Intake Individuals

Individuals following a vegan diet tend to have the lowest intake levels, due to the animal-based sources of taurine. Since taurine is not present in appreciable amounts in plant foods, vegans rely entirely on endogenous synthesis, which may result in lower circulating concentrations, though this does not necessarily produce overt deficiency in healthy adults capable of adequate synthesis.

Drug Interactions and Specific Pharmacological Contexts

The retinal toxicity of the antiepileptic drug vigabatrin is caused by taurine depletion, and taurine supplementation decreased the observed photoreceptor degeneration in animal models. This interaction is clinically documented and has implications for patients treated with vigabatrin.

Depleted serum levels of taurine have been associated with many oxidative stress-induced pathologies. Certain disease states — including renal failure (where taurine renal reabsorption may be impaired), severe dietary restriction, and metabolic disorders — can affect taurine homeostasis and may warrant monitoring or supplementation under clinical guidance.

Human studies available for risk assessment were not of sufficient quality (due to low number of participants, non-healthy populations, and short duration) to be used as the sole basis for risk characterization. This limitation applies equally to both safety and efficacy assessments, and further large-scale, long-duration human research is needed across all proposed therapeutic applications.

References

• Ripps H, Shen W. "Review: taurine: a 'very essential' amino acid." Molecular Vision, 2012. PubMed/NIH.
• Schaffer SW, et al. "Effects and Mechanisms of Taurine as a Therapeutic Agent." Biomolecules & Therapeutics, 2018. PMC.
• Militante JD, Lombardini JB. "The potential health benefits of taurine in cardiovascular disease." Journal of Cardiovascular Disease Research, 2008. PMC.
• Liu X, et al. "Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis." Nutrition Journal, 2024. PMC.
• Bkaily G, Jacques D. "Functional Role of Taurine in Aging and Cardiovascular Health: An Updated Overview." Nutrients, 2023. PMC.
• Elbarbary NS, et al. "The Anti-Inflammatory Effect of Taurine on Cardiovascular Disease." Nutrients, 2020. PMC.
• Mero A, et al. "Taurine in sports and exercise." Journal of the International Society of Sports Nutrition, 2021. PMC.
• Waldron M, et al. "The Dose Response of Taurine on Aerobic and Strength Exercises: A Systematic Review." Nutrients, 2021. PMC.
• Arazi H, et al. "Taurine supplementation enhances anaerobic power in elite speed skaters: A double-blind, randomized, placebo-controlled, crossover study." PMC, 2023.
• Singh P, et al. "Taurine deficiency as a driver of aging." Science, 2023.
• "Experimental Evidence Against Taurine Deficiency as a Driver of Aging in Humans." PMC, 2025.
• NIH News Release: "NIH researchers conclude that taurine is unlikely to be a good aging biomarker." National Institutes of Health, 2025.
• Froger N, et al. "Taurine: a promising nutraceutic in the prevention of retinal degeneration." PMC, 2023.
• "Taurine Provides Neuroprotection against Retinal Ganglion Cell Degeneration." PMC, 2012.
• Tang X, et al. "Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials." Nutrition & Diabetes, 2024. PMC.
• "Neuroprotective Mechanisms of Taurine against Ischemic Stroke." PMC, 2014.
• Takahashi K, et al. "Quality and safety issues related to traditional animal medicine: role of taurine." Journal of Biomedical Science, 2010. PMC.
• "Taurine and inflammatory diseases." PMC, 2014.
• "Physiological roles of taurine in heart and muscle." PMC, 2010.
• Bhatt DL, et al. "The Role of Taurine in Mitochondria Health: More Than Just an Antioxidant." Molecules, 2021. MDPI.
• EFSA. "EFSA adopts opinion on two ingredients commonly used in some energy drinks." European Food Safety Authority, 2009.
• FDA. Agency Response Letter GRAS Notice No. GRN 000586 — Taurine. U.S. Food and Drug Administration.
• Costantini MV, et al. "Caffeine, D-glucuronolactone and Taurine Content in Energy Drinks: Exposure and Risk Assessment." PMC, 2022.
• Baliou S, et al. "Taurine Supplementation as a Neuroprotective Strategy upon Brain Dysfunction in Metabolic Syndrome and Diabetes." Nutrients, 2022. PMC.
• Wikipedia: Taurine — for chemical formula and nomenclature reference.
• Bhatt DK, et al. "Taurine in Congestive Heart Failure." International Journal of Clinical Cardiology, 2021.
• Chen L, et al. "Taurine ameliorates blood pressure and vascular function in patients with type 2 diabetes: Randomized, double-blind, placebo-controlled trial." PMC, 2025.
• "The effect of taurine supplementation on markers of muscle damage and muscle pain in an athletic population: A systematic review and meta-analysis." Heliyon, 2025.